Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Crump

Showing results (121-130 of 183) with videos related to

Pageof 19
Sort By:
Blood Advances|January 16, 2026
Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphomaTiana Kordbacheh, Kelvin Kw Chan, Michael Crump, et al.
Human Genetics|December 7, 2010
Investigation of 15 of the top candidate genes for late-onset Alzheimer's diseaseOlivia Belbin, Minerva M Carrasquillo, Michael Crump, et al.
Blood Neoplasia|October 28, 2025
Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapyChathuri Abeyakoon, Sita Bhella, Katrina Hueniken, et al.
British Journal of Haematology|February 19, 2020
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorderMichael D Jain, Ryan Lam, Zhihui Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Seminars in Oncology|February 1, 2017
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Seminars in Oncology|February 14, 2002
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Blood Neoplasia|June 8, 2026
A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)Sarit Assouline, Anca Prica, Diego Villa, et al.
Molecular Informatics|August 3, 2016
The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity TestingPekka Kohonen, Emilio Benfenati, David Bower, et al.
Journal of the National Cancer Institute|December 18, 2016
General Biomarker Recommendations for LymphomaLisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Pageof 19

Showing results (121-130 of 183) with videos related to

Sort By:
Pageof 19
Blood Advances|January 16, 2026
Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphomaTiana Kordbacheh, Kelvin Kw Chan, Michael Crump, et al.
Human Genetics|December 7, 2010
Investigation of 15 of the top candidate genes for late-onset Alzheimer's diseaseOlivia Belbin, Minerva M Carrasquillo, Michael Crump, et al.
Blood Neoplasia|October 28, 2025
Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapyChathuri Abeyakoon, Sita Bhella, Katrina Hueniken, et al.
British Journal of Haematology|February 19, 2020
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorderMichael D Jain, Ryan Lam, Zhihui Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Seminars in Oncology|February 1, 2017
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Seminars in Oncology|February 14, 2002
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Blood Neoplasia|June 8, 2026
A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)Sarit Assouline, Anca Prica, Diego Villa, et al.
Molecular Informatics|August 3, 2016
The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity TestingPekka Kohonen, Emilio Benfenati, David Bower, et al.
Journal of the National Cancer Institute|December 18, 2016
General Biomarker Recommendations for LymphomaLisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Pageof 19